24 September 2026 · MHRA
MHRA appoints five new commissioners to human medicines body
The Medicines and Healthcare products Regulatory Agency has announced the appointment of five new commissioners to the Commission on Human Medicines. The commission operates as an independent advisory body that provides expert advice to UK health ministers and licensing authorities on matters relating to the safety, quality and efficacy of medicines.
Under its statutory remit, the Commission on Human Medicines assesses scientific evidence, clinical data, and post-market safety information to support national regulatory decision-making. The advice provided by the group informs ministerial and agency decisions on product licensing, safety warnings, changes to medicinal classifications, and ongoing pharmacovigilance measures across the United Kingdom. The appointment of five new commissioners brings additional advisory capacity to the panel as it delivers independent assessments on pharmaceutical safety and quality standards.
The regulatory announcement did not detail specific clinical portfolios or committee assignments for the new appointees, stating plainly that the members will contribute to the ongoing statutory work of the commission. The advisory group will continue to review scientific evidence and issue recommendations on therapeutic products, monitoring ongoing safety profiles and regulatory compliance in line with UK legislation.
For UK online pharmacies and prescribing brands, the administrative update has no immediate operational impact on dispensing practices, though clinical teams should keep track of routine regulatory advice and guidance issued by the commission.